Back to results
US 2017/0319667 A9Published application
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
AssigneeRevance Therapeutics, Inc.
InventorGary E. Borodic
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
Claims20
A method of treating depression comprising the steps of:
- a) identifying a subject with a depressive disorder or identifying a subject with one or more symptoms of a depressive disorder;
- and
- b) administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of depression.
A method of treating a depressive disorder comprising the steps of:
- a) identifying a subject with a depressive disorder or identifying a subject with one or more symptoms of a depressive disorder;
- b) administering to said subject a composition comprising a neurotoxin and a pharmaceutically acceptable carrier wherein said composition is delivered across a blood brain barrier in an amount sufficient to decrease cholinergic neuron transmission.
Dependencies are inferred from the claim text.